Department of Physics and Astronomy, University of British Columbia, Vancouver, British Columbia, Canada.
BC Cancer, Abbotsford Center, Abbotsford, British Columbia, Canada.
J Appl Clin Med Phys. 2022 Dec;23(12):e13815. doi: 10.1002/acm2.13815. Epub 2022 Nov 10.
Volume staging involves dividing the target volume into smaller parts and treating each part separately. In this study, the feasibility of volume-staged stereotactic radiosurgery (VS-SRS) on a linear accelerator using volumetric modulated arc therapy (VMAT) and a frameless patient positioning system is investigated. Ten patients, previously treated with hypofractionated stereotactic radiotherapy with arteriovenous malformation (AVM) sized from 1.6 to 4.0 cm in diameter, were selected. VS-SRS plans were created with the VMAT technique on the Varian Eclipse treatment planning system (TPS) using the TrueBeam STx linear accelerator. For each patient, an AVM-VMAT set was planned with the AVM as the target and a PTV-VMAT set using the (PTV = AVM+1 mm) as the target. All targets were divided into two sub-volumes. The TPS data from the AVM-VMAT plans was compared to Gamma Knife (GK) VS-SRS plan data available in the literature. The AVM-VMAT and PTV-VMAT plans were compared to investigate the effect of a 1 mm PTV margin on normal brain (NB) dose. End-to-end testing was performed using a GaFchromic EBT3 film and point-dose measurements. Dosimetric effects of multiple setups were investigated through film-to-film comparisons. Median target dose coverage, NB V , and conformity index for the AVM-VMAT plans were 97.5%, 17 cm , and 0.8, respectively. PTV-VMAT plans attained comparable target dose coverage, but the average NB V increased by 48.9% when compared to the AVM-VMAT plans. Agreement of point-dose measurements with TPS calculations was -0.6% when averaged over all patients. Gamma analysis passing rates were above 90% for all film-to-film comparisons (2%/1 mm criteria), and for the film to TPS comparison (5%/1 mm). This work suggests that VMAT is capable of producing VS-SRS plans with similar dose falloff characteristics as GK plans. NB dose depends on PTV margin size, and two-stage treatment setups do not appear to contribute additional uncertainty to treatment delivery.
体积分期涉及将靶体积分成更小的部分,并分别治疗每个部分。在这项研究中,研究了使用容积调制弧形治疗(VMAT)和无框架患者定位系统在直线加速器上进行体积分期立体定向放射外科(VS-SRS)的可行性。选择了 10 名先前接受过动静脉畸形(AVM)大小为 1.6 至 4.0 厘米的分割立体定向放射治疗的患者。使用瓦里安 Eclipse 治疗计划系统(TPS)上的 VMAT 技术为每个患者创建 VS-SRS 计划,使用 TrueBeam STx 直线加速器。对于每个患者,计划了一个 AVM-VMAT 集,将 AVM 作为目标,并用 PTV-VMAT 集将(PTV=AVM+1mm)作为目标。所有目标均分为两个子体积。将 AVM-VMAT 计划的 TPS 数据与文献中可用的伽玛刀(GK)VS-SRS 计划数据进行比较。比较 AVM-VMAT 和 PTV-VMAT 计划,以研究 1mm PTV 边缘对正常脑(NB)剂量的影响。使用 GaFchromic EBT3 胶片和点剂量测量进行端到端测试。通过胶片到胶片比较研究了多个设置的剂量学影响。AVM-VMAT 计划的靶区剂量覆盖率、NB V 和适形指数中位数分别为 97.5%、17cm 和 0.8。PTV-VMAT 计划达到了可比的靶区剂量覆盖率,但与 AVM-VMAT 计划相比,NB V 平均增加了 48.9%。所有患者平均而言,点剂量测量与 TPS 计算的一致性为-0.6%。所有胶片到胶片比较(2%/1mm 标准)和胶片到 TPS 比较(5%/1mm)的伽马分析通过率均高于 90%。这项工作表明,VMAT 能够生成与 GK 计划具有相似剂量衰减特性的 VS-SRS 计划。NB 剂量取决于 PTV 边缘大小,两阶段治疗设置似乎不会给治疗提供增加额外的不确定性。